Compare KB Financial Group, Inc. (KB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Organon & Co. Common Stock — how do they compare? KB Financial Group, Inc. trades at $115.32 (market cap $41.70B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: KB Financial Group, Inc. is far larger — about 11.6× Organon & Co. Common Stock's market cap, and KB Financial Group, Inc. pays the higher dividend (2.83%). Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Organon & Co. Common Stock for 0 Days on average.
| KB | OGN | |
|---|---|---|
Market Cap | $41.70B | $3.61B |
Volume | 251,007 | 1,808,049 |
Sector | Financials | Health |
52-Week High | $132.88 | $13.81 |
52-Week Low | $80.15 | $5.70 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $213.39T | $11.03B |
Dividend Yield | 2.83% | 0.58% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
